Trial Profile
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents With Oral Corticosteroid Dependent Asthma (TROPOS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Mar 2019
Price :
$35
*
At a glance
- Drugs Tralokinumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms TROPOS
- Sponsors AstraZeneca
- 15 Nov 2018 Results assessing efficacy of oral corticosteroid-sparing potential of Tralokinumab in patients with severe asthma, published in the European Respiratory Journal.
- 19 Sep 2018 Results presented at the 28th Annual Congress of the European Respiratory Society
- 01 Nov 2017 According to an AstraZeneca media release, full data from the study will be presented at a forthcoming medical meeting.